Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb;1(2):e39.
doi: 10.1002/cpz1.39.

Cap 1 Messenger RNA Synthesis with Co-transcriptional CleanCap® Analog by In Vitro Transcription

Jordana M Henderson  1 , Andrew Ujita  1 , Elizabeth Hill, Sally Yousif-Rosales  1 , Cory Smith  1 , Nicholas Ko  1 , Taylor McReynolds  1 , Charles R Cabral  1 , Julienne R Escamilla-Powers  1 , Michael E Houston  1
Affiliations

Cap 1 Messenger RNA Synthesis with Co-transcriptional CleanCap® Analog by In Vitro Transcription

Jordana M Henderson et al. Curr Protoc. 2021 Feb.

Erratum in

Abstract

Synthetic messenger RNA (mRNA)-based therapeutics are an increasingly popular approach to gene and cell therapies, genome engineering, enzyme replacement therapy, and now, during the global SARS-CoV-2 pandemic, vaccine development. mRNA for such purposes can be synthesized through an enzymatic in vitro transcription (IVT) reaction and formulated for in vivo delivery. Mature mRNA requires a 5'-cap for gene expression and mRNA stability. There are two methods to add a cap in vitro: via a two-step multi-enzymatic reaction or co-transcriptionally. Co-transcriptional methods minimize reaction steps and enzymes needed to make mRNA when compared to enzymatic capping. CleanCap® AG co-transcriptional capping results in 5 mg/ml of IVT with 94% 5'-cap 1 structure. This is highly efficient compared to first-generation cap analogs, such as mCap and ARCA, that incorporate cap 0 structures at lower efficiency and reaction yield. This article describes co-transcriptional capping using TriLink Biotechnology's CleanCap® AG in IVT. © 2021 Wiley Periodicals LLC. Basic Protocol 1: IVT with CleanCap Basic Protocol 2: mRNA purification and analysis.

Keywords: CleanCap; cap 1; cap analog; in vitro transcription; messenger RNA.

PubMed Disclaimer

References

Literature Cited

    1. Armstrong, J. A., & Schulz, J. R. (2008). Agarose gel electrophoresis. Current Protocols Essential Laboratory Techniques, 00, 7.2.1-7.2.20. doi: 10.1002/9780470089941.et0702s00.
    1. Aviv, H., & Leder, P. (1972). Purification of biologically active globin messenger RNA by chromatography on oligothymidylic acid−cellulose. Proceedings of the National Academy of Sciences of the United States of America, 69(6), 1408-1412.
    1. Azarani, A., & Hecker, K. H. (2001). RNA analysis by ion-pair reversed-phase high performance liquid chromatography. Nucleic Acids Research, 29(2), e7. doi: 10.1093/nar/29.2.e7.
    1. Baiersdörfer, M., Boros, G., Muramatsu, H., Mahiny, A., Vlatkovic, I., Sahin, U., & Karikó, K. (2019). A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA. Molecular Therapy Nucleic Acids, 15, 26-35. doi: 10.1016/j.omtn.2019.02.018.
    1. Chamberlin, M., & Ring, J. (1973). Characterization of T7-specific ribonucleic acid polymerase. 1. General properties of the enzymatic reaction and the template specificity of the enzyme. The Journal of Biological Chemistry, 248(6), 2235-2244. doi: 10.1016/S0021-9258(19)44211-7.

LinkOut - more resources